AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02616536 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Teaching methods
Description: the two teaching methods will be given to two groups of students and their knowledge gain will be analysed
Study NCT01938560 — intervention group
Intervention type: OTHER
Intervention: Survey Responses
Description: Subject understanding of the risk of urinary retention and the symptoms of acute urinary retention associated with retigabine will be assessed using the survey instrument.
Study NCT01046968 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lepticore
Description: 300 mg twice daily
Study NCT03793413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lingual frenotomy
Description: A lingual frenotomy will be performed using a CO2 laser - using the NFANT bottle feeding system, the intervention arm will be compared against the observation arm to determine if there are changes in lingual mobility parameters during bottle feeding.
Study NCT02078232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: puncture of head of pancreas
Description: puncture of head of pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control.~randomization: puncture with either 22G needle or 19G flex needle
Study NCT02078232 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: puncture of head of pancreas
Description: puncture of head of pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control.~randomization: puncture with either 22G needle or 19G flex needle
Study NCT01939691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluprednate
Description: Difluprednate 0.05% - corticosteroid eyedrop
Study NCT01939691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac
Description: Nepafenac 0.1% - NSAID eyedrop
Study NCT01939691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone acetate
Description: prednisolone acetate 1% - corticosteroid eyedrop
Study NCT03392038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thin ADM
Description: Use of soft tissue allograft for root coverage
Study NCT03392038 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thick ADM
Description: Periodontal surgical procedure to coronally position the tissue over the ADM allograft
Study NCT01032668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: high dose clopidogrel continuing after percutaneous coronary intervention
Study NCT00366249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tigecycline
Description: 150 mg Tigecycline once-daily IV infusion for up to 28 days, or 42 days for the substudy wth osteomyelitis
Study NCT00366249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem
Description: Ertapenem 1g IV infusion every 24 hours +/- vancomycin depending on culture results and at the discretion of investigator (for coverage of Methicillin-resistant Staphylococcus aureus (MRSA), coagulase-negative staphylococci (CNS) or enterococci coverage).
Study NCT00829036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wayfinding Prototype
Description: A Wayfinding Prototype is used by subjects to determine any advantages over current standard of rehabilitation.
Study NCT02460549 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: therapeutic education program
Study NCT03428295 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dose Safety AP system
Description: Device will be used to automatically dose insulin
Study NCT01525420 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance Therapy (ACT)
Description: ACT
Study NCT01525420 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: CBT
Study NCT00964249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444
Description: Long acting Beta 2 agonist
Study NCT00964249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT03049930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine is a medication used for starting and maintaining anesthesia. Participants randomized to the ketamine arm will receive 1 mg/ml solution infused at 0.2 mg/kg/hour (0.2 ml/kg/h) for a maximum of 20 ml/hour.
Study NCT03049930 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Participants randomized to the placebo arm will receive 0.9 mg/ml sodium chloride, infused at a rate of 0.2 ml/kg/hour
Study NCT01804842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Met DR
Description: metformin delayed-release tablets
Study NCT01804842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Met DR
Description: metformin delayed-release tablets
Study NCT01425307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Capsules (300 mg, 400 mg, or 500 mg) taken once daily liquid formulation (100 mg/mL)
Study NCT01791465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended-release exenatide
Description: Single arm study - 2mg Bydureon every 7 days x 16 weeks
Study NCT03935490 — intervention group
Intervention type: PROCEDURE
Intervention: emergency transrectus sheath pre-peritoneal mesh repair (e-TREPP)
Description: The Trans REctussheath PrePeritoneal mesh repair (TREPP) was developed in 2006 as an open preperitoneal technique to reduce CPIP. In short: a 4-5 centimeters (cm) transverse incision is made about 1 cm above the localization of the deep inguinal ring. The anterior rectus sheath is opened. After retracting the rectus muscle medially, the preperitoneal space (PPS) is bluntly dissected and a complete overview can be achieved. All possible hernia orifices can be visualized such as: a direct, indirect, pantaloon, and/or femoral hernia. A self-expandable mesh is then positioned in the PPS. Due to the upstream principle no mesh fixation is necessary.
Study NCT02373566 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novomaix dermal substitute in combination with STSG
Description: Novomaix dermal substitute in combination with STSG
Study NCT04530968 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT02078089 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Morphine
Description: Morphine will be given to patients as part of their standard care
Study NCT02078089 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxcarbazepine
Description: Can be taken with or without food at the same time as morphine. Morphine will be provided to patients free of charge.
Study NCT02488148 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hot yoga
Description: Subjects in the two intervention groups will complete the standard 26-posture Bikram yoga series in a studio heated at 41ºC (traditional environment) or in a studio at a room temperature of 22ºC whereas control group subjects will be instructed to maintain physical activity patterns for the 12-week study duration. Yoga classes will be held at the Pure Bikram Yoga downtown Austin location. Classes will be completed 3 times weekly for 12 weeks and consist of 90 minutes of yoga postures and breathing exercises.
Study NCT02488148 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-heated yoga
Description: Subjects in the two intervention groups will complete the standard 26-posture Bikram yoga series in a studio heated at 41ºC (traditional environment) or in a studio at a room temperature of 22ºC whereas control group subjects will be instructed to maintain physical activity patterns for the 12-week study duration. Yoga classes will be held at the Pure Bikram Yoga downtown Austin location. Classes will be completed 3 times weekly for 12 weeks and consist of 90 minutes of yoga postures and breathing exercises.
Study NCT03144830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton
Description: This is an open study and so all participants involved with be using the exoskeleton to determine the safety and feasibility of its use during the acute rehabilitation phase.
Study NCT02792283 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: whole blood collection
Study NCT03152188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMT
Description: Fifteen FMT Openbiome capsules administered at the same time
Study NCT03152188 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fifteen placebo capsules administered at the same time
Study NCT00693693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocortisone 17-butyrate 0.1% Cream preparation
Description: Apply medication twice a day to affected areas of atopic dermatitis
Study NCT00693693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocortisone 17-butyrate 0.1% Ointment preparation
Description: Apply medication twice a day to affected areas of atopic dermatitis
Study NCT00693693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocortisone 17-butyrate 0.1% Lipocream preparation
Description: Apply medication twice a day to affected areas of atopic dermatitis
Study NCT02533076 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Challenge agent: capsaicin
Description: During the study period (Day 1), in each subject 3 equally spaced (minimum distance of 4 cm) 10-mm rubber O-rings (8 mm inner diameter) will be placed on the volar surface of the forearm. The most proximal ring (i.e. at least 15 cm proximal of the wrist crease) is referred to as ring number 1; the most distal ring is referred to as ring number 3; in between is ring number 2.~In ring number 1 and 2, subjects will receive a topical dose of 1000 µg/20 µL capsaicin (single-blind). Change in dermal blood flow induced by capsaicin will be measured with Laser Doppler Imaging.
Study NCT02533076 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Challenge agent: placebo
Description: During the study period (Day 1), in each subject 3 equally spaced (minimum distance of 4 cm) 10-mm rubber O-rings (8 mm inner diameter) will be placed on the volar surface of the forearm. The most proximal ring (i.e. at least 15 cm proximal of the wrist crease) is referred to as ring number 1; the most distal ring is referred to as ring number 3; in between is ring number 2.~In ring number 3, subjects will receive a topical dose of placebo (single-blind).Change in dermal blood flow induced by placebo will be measured with Laser Doppler Imaging.
Study NCT02533076 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Mechanical stimulation with Von Frey filaments
Description: Von Frey filaments will be used to measured the mechanical detection and pain threshold of the volunteers. The Von Frey filaments will be applied on the upper capsaicin spot in sequential order. The subject will be asked to indicate when he feels the application of the Von Frey filaments and when it hurts.
Study NCT02533076 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Temperature sensitivity measurement with Advanced Thermal Stimulation
Description: Temperature sensitivity (detection and pain threshold) will be determined using Advanced Thermal stimulation. A thermode will be attached to the hand of the volunteer with a baseline temperature of 32°C. The thermode will heat up and cool down with a rate of 1°C/second and the volunteer will be asked to click on a computer mouse when he feels the change in temperature and when it hurts.
Study NCT02541500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Oral minocycline 200 mg daily will be started on day six of treatment for a period of four months
Study NCT04348188 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education program on healthy habits
Description: 6-week supervised educational program with 12-month follow-up compared to the same unsupervised intervention
Study NCT04348188 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education program on healthy habits
Description: 6-week supervised educational program with 12-month follow-up compared to the same unsupervised intervention
Study NCT02163668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Group
Description: 8 months of Yoga training
Study NCT01807611 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Lymphoid Irradiation
Description: Participants receive total lymphoid irradiation over four doses.
Study NCT01807611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV.
Study NCT01807611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV.
Study NCT01807611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV.
Study NCT00277355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: minocycline
Description: Minocycline: Oral; minocycline 100 mg capsules administered twice a day with the morning and evening meal (\~ 8 hours apart)
Study NCT00277355 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching placebo 1 capsule twice daily, 18 months treatment duration.
Study NCT00246805 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitatron pacemaker C20 SSIR or T20 SSIR models
Description: VRS: special function that automatically adapts pacing rate to regularize cardiac cycles
Study NCT01807611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV.
Study NCT01807611 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPC,A Infusion
Description: Participants received infusions of HPC,A (CD34+ selected) and HPC,A (CD45RA depleted).
Study NCT01807611 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TC-NK Infusion
Description: Participants receive infusions of TC-NK.
Study NCT01807611 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Participants receive G-CSF subcutaneously or intravenously.~Donors receive G-CSF subcutaneously during cell mobilization.
Study NCT01807611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide.
Study NCT01807611 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
Study NCT01807611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Given intravenously or orally.
Study NCT00683501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNB-001
Description: four dosages of DNB-001, one placebo dosage
Study NCT00683501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DNB-001
Description: four dosages of DNB-001, one placebo dosage
Study NCT01525524 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: In active stimulation(active Transcranial Direct Current Stimulation), the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.
Study NCT01525524 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: In active stimulation(active Transcranial Direct Current Stimulation), the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.
Study NCT03924427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Oral tablet administration
Study NCT02688725 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: post mastectomy ultrasound
Description: post mastectomy ultrasound
Study NCT03394118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: A cycle of study treatment is defined as 28 days. Each subject will continue the study drug(Osimertinib) until disease progression or manifestation of unacceptable toxicity during the study period. The study drug will be administered orally as one 80 mg tablet once a day. The initial dose of the study drug 80 mg daily can be reduced to 40 mg once daily.
Study NCT01942304 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Calcium phosphosilicate alloplastic bone putty in direct sinus augmentation
Study NCT01942304 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anorganic bovine bone mineral in direct sinus augmentation
Study NCT00493714 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Surveys lasting 30 minutes or more.
Study NCT02287805 — intervention group
Intervention type: OTHER
Intervention: qualitative survey
Study NCT02287805 — intervention group
Intervention type: OTHER
Intervention: quantitative survey
Study NCT06004193 — intervention group
Intervention type: BEHAVIORAL
Intervention: Exercise
Description: At least 150 minutes of exercise in a week
Study NCT05247060 — intervention group
Intervention type: OTHER
Intervention: no experimental intervention
Description: There will not be any experimental intervention. The study will be conducted according with normal clinical practice
Study NCT01962467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/LEV FDC
Description: Intranasal aqueous microsuspension containing 25.0 microgram (µg) of FF and 50 µg of LEV as a fixed dose combination. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
Study NCT01962467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF
Description: Intranasal aqueous microsuspension containing 27.5µg of FF. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
Study NCT01962467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEV
Description: Intranasal aqueous microsuspension containing 50 µg of LEV. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
Study NCT03923504 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Intervention (PAI)
Description: Those who opt-in to attend in-person study visits and to undergo COVID testing will also complete an MRI exam and CPET testing. Participants unwilling to have COVID testing done will only complete an MRI exam and home-based testing. All testing will take place either within 6 weeks of initiating systemic treatments or within 8 weeks of completing radiation then at 3 \& 6 months. Patients may participate in 1-2 training sessions per week offered under the direct supervision of a master's level clinical exercise physiologist, as well as 1-2 sessions at home. PAI sessions consist of slow aerobic warm-up, followed by 20 minutes of strength training,15 minutes of progressive intensity aerobic exercise (AE), and then 10 minutes of stretching for cool-down. Participants will have the ability to participate in training sessions facilitated via online channels at home.
Study NCT03923504 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living Control
Description: Patients randomized to the control arm will either attend online sessions via secure video conferencing (e.g. Zoom) or telephone or to come to a centralized meeting location (if safety allows) to participate in organized health workshops. Session attendance will be required 2 times/month (over the 6 months). Make up sessions will be offered for those participants who have to miss a group session. Each session lasts 60 minutes and matches the number of visits made by the PAI group as much as possible.
Study NCT03660280 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Specific probiotic lactobacilli (added to stabilized ongoing treatment)
Study NCT03660280 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03812783 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hepatic arterial infusion chemotherapy
Description: administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
Study NCT03812783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folfox Protocol
Description: Oxaliplatin , fluorouracil, and leucovorin
Study NCT03812783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: administration of Sorafenib
Study NCT03812783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: administration of Sorafenib
Study NCT03812783 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion chemotherapy
Description: administration of Irinotecan, Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
Study NCT03812783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: Irinotecan, Oxaliplatin , fluorouracil, and leucovorin